Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the multicenter AIDS cohort study

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 3, 2008, Pages 281-288

  Riddler, Sharon A ^a,f   Li, Xiuhong ^b   Otvos, James ^c   Post, Wendy ^b   Palella, Frank ^d   Kingsley, Lawrence ^a   Visscher, Barbara ^e   Jacobson, Lisa P ^b   Sharrett, A R ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c LIPOSCIENCE INC   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antiretroviral drugs; Dyslipidemia; HIV 1 infection; Lipoprotein subclasses; Nuclear magnetic resonance spectroscopy

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; LIPOPROTEIN; PROTEINASE INHIBITOR;

ADULT; ARTICLE; ATHEROGENESIS; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHENOTYPE; PRIORITY JOURNAL; REGRESSION ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; RITONAVIR;

EID: 47049107144     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31817bbbf0     Document Type: Article

References (32)

1. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1991;90:154-162.
2. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052.
3. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-2982.
4. El-Sadr W, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005;6:114-121.
5. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
6. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. New Engl J Med. 2003;349:1993-2003.
7. Friis-Moller N, Reiss P, El-Sadr W, et al. Exposure to PI and NNRTI and Risk of Myocardial Infarction: Results From the D:A:D Study:Program and Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections, 5-8 February 2006. Denver, CO. Abstract 144.
8. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360: 1747-1748.
9. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26:847-870.
10. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2002;22: 1175-1180.
11. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556-1563.
12. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-1) trial. Am J Cardiol. 2002;90:89-94.
13. Mora S, Moyses S, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;192:211-217.
14. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52:453-462.
15. Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495-506.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
17. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.
18. Asztalos BF, Schaefer EJ, Horvath KV, et al. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis. 2006;184:72-77.
19. Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS. 2005;19:917-925.
20. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naïve subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005;19:1807-1818.
21. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36:1011-1019.
22. Allain CC, Poon LS, Chan CSG, et al. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-475.
23. Warnick GR, Albers JJ. A comprehensive evaluation of heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res. 1978;19:65-76.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-508.
25. Rifai N, Iannotti E, DeAngelis K, et al. Analytical and clinical performance of a homogeneous enzymatic LDL-cholesterol assay compared with the ultracentrifugation-dextran sulfate-Mg2+ method. Clin Chem. 1998;44:1242-1250.
26. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973;19:476-482.
27. Georgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort Study experience. Clin Immunol Immunopathol. 1990;55: 173-186.
28. DiMango EP, Corle D, O'Brien JF, et al. Effect of long-term freezer storage, thawing, and refreezing on selected constituents of serum. Mayo Clin Proc. 1989;64:1226-1234.
29. Petrakis NL. Biologic banking in cohort studies, with special reference to blood. Natl Cancer Inst Monogr. 1985;67:193-198.
30. DHHS/Henry J. Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. May 2006 revision. Available at: http://aidsinfo.nih.gov. Accessed July 1, 2007.
31. Feingold KR, Krauss RM, Pang M, et al. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass B. J Clin Endocrinol Metab. 1993;76:1423-1427.
32. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001; 104:257-262.